Alpha Cognition Inc. (OTCQB: ACOGF) is a clinical stage, biopharmaceutical company dedicated to developing treatments for under-served neurodegenerative diseases, such as Alzheimer's Dementia and ALS. CEO Michael McFadden joins us to break down the types of neurodegenerative diseases that are targeted in the company’s programs.

View Podcast Transcript for Alpha Cognition